PROCEPT BioRobotics Corp. (PRCT)

PROCEPT BioRobotics Corp.'s stock price has significantly declined over the past year. Key events impacting the stock in the past six months include the Q3 2025 earnings report, which showed a revenue increase and growth in the U.S. installed base. The Q4 2025 earnings report revealed increased revenue and procedure volume but a revenue miss and changes in rebate programs triggered a stock drop. The company detailed its market opportunity, long-term strategy, growth goals, and financial guidance for 2026-2027 at the 2026 Investor Day. The international launch of the HYDROS Robotic System in the UK was announced. The European Association of Urology guidelines upgraded Aquablation therapy to a strong surgical recommendation for BPH. The company is scheduled to report its first-quarter 2026 financial results.

Explicit information on demand seasonality for PROCEPT BioRobotics' products and services is not directly available. The company's Q4 2025 report indicated its highest procedure volume to date and strongest capital quarter for system sales. However, a decline in revenue from Q3 to Q4 2025 was attributed to a one-time ordering hurdle related to rebate elimination, rather than inherent seasonality. The company's focus on expanding its installed base and increasing utilization of its systems suggests a drive for consistent demand.

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company focused on advancing urological patient care through transformative solutions. The company operates in the Healthcare sector, specifically within the Medical Devices and Instruments industry. Its main products are the AQUABEAM and HYDROS Robotic Systems, which are advanced, image-guided surgical robotic systems used in minimally invasive urologic surgery, primarily for treating benign prostatic hyperplasia (BPH). The AQUABEAM system delivers Aquablation therapy, combining real-time imaging, personalized planning, automated robotics, and heat-free waterjet ablation. The HYDROS Robotic System is noted as the only AI-powered robotic technology that delivers Aquablation therapy.

PROCEPT BioRobotics Corp. generates most of its revenue from the United States. The company also has an international presence and plans for further global expansion. The HYDROS Robotic System recently launched internationally in the UK, with additional international expansion expected in 2026.

PROCEPT BioRobotics' brand reputation has seen both positive developments and challenges in the past year. Positive events include the upgrade of Aquablation therapy in the European Association of Urology guidelines and the international launch of the HYDROS Robotic System. However, investor alert announcements from law firms investigating claims on behalf of investors, citing a Q4 revenue miss and concerns about pricing headwinds, could negatively impact its reputation.

PROCEPT BioRobotics Corporation has significant institutional ownership, with 267 institutional owners and shareholders holding 99.51% of the stock. Major institutional owners include Vanguard Group Inc., Fmr Llc, and BlackRock, Inc. Individual insiders hold 31.67% of the company's stock, with Cpmg Inc. being the largest individual shareholder.